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Abstract
Background: Systematic reviews suggest that the incidence of diagnosed tuberculosis is two- to- three times
higher in those with diabetes mellitus than in those without. Few studies have previously reported the association
between diabetes or hyperglycaemia and the prevalence of active tuberculosis and none in a population-based
study with microbiologically-defined tuberculosis. Most have instead concentrated on cases of diagnosed
tuberculosis that present to health facilities. We had the opportunity to measure glycaemia alongside prevalent
tuberculosis. A focus on prevalent tuberculosis enables estimation of the contribution of hyperglycaemia to the
population prevalence of tuberculosis.
Methods: A population-based cross-sectional study was conducted among adults in 24 communities from Zambia
and the Western Cape (WC) province of South Africa. Prevalent tuberculosis was defined by the presence of a
respiratory sample that was culture positive for M. tuberculosis. Glycaemia was measured by random blood glucose
(RBG) concentration. Association with prevalent tuberculosis was explored across the whole spectrum of glycaemia.
Results: Among 27,800 Zambian and 11,367 Western Cape participants, 4,431 (15.9%) and 1,835 (16.1%) respectively
had a RBG concentration ≥7.0 mmol/L, and 405 (1.5%) and 322 (2.8%) respectively had a RBG concentration ≥11.
1 mmol/L. In Zambia, the prevalence of tuberculosis was 0 · 5% (142/27,395) among individuals with RBG
concentration <11.1 mmol/L and also ≥11.1 mmol/L (2/405); corresponding figures for WC were 2 · 5% (272/11,045)
and 4 · 0% (13/322). There was evidence for a positive linear association between hyperglycaemia and pulmonary
prevalent tuberculosis. Taking a RBG cut-off 11.1 mmol/L, a combined analysis of data from Zambian and WC
communities found evidence of association between hyperglycaemia and TB (adjusted odds ratio = 2 · 15, 95% CI
[1 · 17–3 · 94]). The population attributable fraction of prevalent tuberculosis to hyperglycaemia for Zambia and WC
combined was 0.99% (95% CI 0 · 12%–1.85%) for hyperglycaemia with a RBG cut-off of 11.1 mmol/L.
Conclusions: This study demonstrates an association between hyperglycaemia and prevalent tuberculosis in a large
population-based survey in Zambia and Western Cape. However, assuming causation, this association contributes
little to the prevalence of TB in these populations.
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Background
The number of adults with diabetes mellitus globally is
predicted to rise from 382 million in 2013 to 592 million
in 2035 [1–6]. Of those in the world who currently have
diabetes, four out of five live in a low or middle income
country [6]. The burden of the anticipated rise in diabetes
prevalence will fall largely to these low and middle income
countries, the same countries that have some of the high-
est burdens of tuberculosis (TB) worldwide [4, 7].
Associations between diabetes and tuberculosis are in-
creasingly recognised: systematic reviews and meta-
analyses suggest that the incidence of active diagnosed
tuberculosis is two- to- three times higher in those with
diabetes compared to those without diabetes; [8–10] that
diabetes increases the risk of death from diagnosed tu-
berculosis [11], and that diabetes may increase the risk
of tuberculosis relapse [9, 11]. Studies from Africa have
shown even stronger associations between diabetes and
active diagnosed TB; a four-fold increase in diabetes
prevalence was seen in TB patients in Dar es Salaam
compared to the general population; [12] an odds ratio
for TB of 8 · 33 was seen in the Congo comparing those
with diabetes to those without diabetes [13]. As the
prevalence of diabetes rises in locations with a high bur-
den of tuberculosis, a deeper understanding of these as-
sociations is increasingly important.
We had the opportunity to measure glycaemia alongside
tuberculosis in a population-based cross-sectional survey,
which took place as part of the ZAMSTAR (Zambia South
Africa TB and HIV Reduction Study) trial [14–16]. This
trial was a 2 x 2 factorial community randomised trial to
evaluate the impact of two complex interventions on the
prevalence of TB in high HIV prevalence settings in
Zambia and South Africa. The primary outcome for the
study was the prevalence of tuberculosis after three years
of intervention, measured through a cross-sectional sur-
vey of a random sample of adults from each community.
We took this opportunity to also explore the association
between hyperglycaemia and prevalent TB.
Both Zambia and South Africa have national TB con-
trol programmes, with a structured approach to TB
diagnosis, management and control. Sputum smear mi-
croscopy is used for the diagnosis of pulmonary TB in
Zambia. Few health care centres have access to culture
or molecular tests. In South Africa Xpert MTB/RIF was
introduced in 2011 for the diagnosis of pulmonary TB,
though interruption to the supply of cartridges has been
a challenge. Supply of TB medication rarely suffers inter-
ruption and is provided free of charge to patients in both
countries. The situation for diabetes management is less
favourable. In Zambia, point-of-care glucometers are
most commonly used for diagnosis, though frequently
glucometer strips are unavailable. Metformin and gliben-
clamide are widely available but access to alternative oral
hypoglycaemics can be challenging. Insulin is available
but can be difficult to access in remote areas. Storage of
insulin is frequently problematic for patients due to lack
of access to refrigeration. Unlike for TB, diabetes medi-
cation is not provided to patients for free.
Few studies have previously reported the association
between diabetes or hyperglycaemia and prevalent
tuberculosis in the general population, and to our
knowledge none in a population-based study with
microbiologically-defined tuberculosis. Most have con-
centrated on cases of tuberculosis that present to, and
are diagnosed, at health facilities. Two historical studies
did measure the prevalence of tuberculosis in the gen-
eral population; one in Philadelphia, USA in 1946 [17],
the other in Kristianstad, Sweden in 1954 [18]. Both
identified pulmonary TB by chest radiograph, and iden-
tified diabetes through referrals from clinics and
through medical records respectively. Rather than being
based in a general population, other studies that have
focused on tuberculosis prevalence have investigated
the prevalence among patients with diabetes in a clinic
setting or identified through medical records, using ei-
ther no comparison group or clinic patients without
diabetes as a comparison group [10, 19, 20]. Exploration
of the association of hyperglycaemia with prevalent tuber-
culosis in a population-based study allows for estimation
of the contribution of hyperglycaemia to the population
prevalence of tuberculosis.
The aims of this study are therefore to determine the as-
sociation between hyperglycaemia and prevalent tubercu-
losis and to estimate the population attributable fractions
of prevalent tuberculosis to hyperglycaemia, assuming
causation, within our study communities in Zambia and
the Western Cape region of South Africa.
Methods
This population-based cross-sectional study was nested
within a 2 x 2 factorial cluster-randomised trial (the
ZAMSTAR study [14–16]) and undertaken between
January and December 2010 in 24 study communities:
16 from 5 provinces in Zambia and 8 from the Western
Cape province of South Africa. Within each community,
a two-stage cluster sampling design was used to recruit
participants. Exclusion criteria were age <18 years, in-
ability to give informed consent due to disability/incap-
acitation, refusal to submit a respiratory sample and any
persons living in institutional settings.
Each participant was required to give written informed
consent. Individuals and household heads were interviewed
in their homes using structured questionnaires. Each par-
ticipant was requested to produce a spot respiratory sam-
ple for tuberculosis culture. Finger prick capillary blood
was taken for HIV testing and random blood glucose
(RBG) measurement, with pre- and post-test counselling
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for HIV tests. RBG concentration was measured using an
Optium Xceed point-of-care glucometer. All individuals
identified to have abnormal blood glucose or to be HIV
positive were referred to existing local health facilities for
appropriate management.
Data were electronically entered directly onto personal
digital assistants by field staff at the time of data collec-
tion, using pre-programmed questionnaires and result
sheets. All information was downloaded daily into a SQL
(structured query language) database and later exported
into Stata.
All procedures for sputum sample collection and cul-
ture were identical in all study sites. Research staff in
all sites were trained to instruct participants on ad-
equate expectoration to achieve a lower rather than
upper airways sample. Samples were collected daily
from field sites and delivered to the laboratory in each
study community. A standard liquid culture technique
was used to isolate Mycobacterium tuberculosis (MGIT,
Becton Dickinson). Growth detected by culture was iden-
tified using an immunochromatographic assay (Capilia TB),
and all Capilia TB assay positive cultures were confirmed
by 16S ribosomal RNA sequencing. Detailed methods
are described by Ayles et al. in the final report of the
ZAMSTAR trial [16].
The Optium Xceed glucometer uses a whole blood ca-
pillary sample but is calibrated to report the plasma
equivalent result. The results presented here are there-
fore the plasma equivalent glucose concentrations. This
device was chosen because of its documented accuracy
in multiple independent studies combined with its avail-
ability in Zambia and South Africa. It was found to be
one of the most superior glucometers in all published
accuracy studies, with between 84% and 100% of the re-
sults from the finger prick capillary specimen being
within the recommended limits compared to reference
plasma estimation on laboratory analysers [21–27].
When inaccuracy was seen, this was mostly for low ra-
ther than high glucose concentrations [24, 25, 27]. All
research staff were trained on the use of this particular
glucometer and were required to undergo proficiency
testing. Standardised control solution was used for per-
formance checks on test strips and meters.
Ethics approval was granted from the London School
of Hygiene and Tropical Medicine Ethics Committee,
the University of Stellenbosch Human Research Ethics
Committee and the University of Zambia Biomedical Re-
search Ethics Committee.
Definitions
 Hyperglycaemia, the exposure of interest for this
study, is initially examined with RBG concentration
as an ordered categorical variable. We then use
sequential RBG cut-offs – 7.0 mmol/L, 7.8 mmol/L,
9.0 mmol/L and 11.1 mmol/L – to explore increas-
ing levels of hyperglycaemia. We based our cut-off
levels on the current World Health Organisation
guidelines for diabetes diagnosis and monitoring
[28], though this was only to allow for exploration
of increasing levels of glycaemia and not intended
to be indicative of diabetes diagnoses.
 Prevalent pulmonary tuberculosis, the outcome of
interest for this study, is defined by the presence
of a respiratory sample that is culture positive for
Mycobacterium tuberculosis.
 HIV status is defined by a combination of blood
sampling plus self-report for those with missing
biological data.
Analysis strategy
Principal components analysis was used to create a
measure of household socio-economic position separ-
ately for each country. Unadjusted and adjusted odds ra-
tios of the association between hyperglycaemia and
prevalent tuberculosis were estimated using logistic re-
gression analysis, accounting for within-cluster correl-
ation resulting from the sampling design. Analyses were
performed separately for Zambian and South African
data due to heterogeneity between the two distinct loca-
tions. This enabled us to control for confounding differ-
ently for each location, which was necessary because of
the big differences between the two settings. Fixed-
effects meta-analysis of adjusted odds ratios from each
country was then performed, with weights according to
the inverse variance method to give overall odds ratios
of the association between hyperglycaemia and prevalent
tuberculosis. Population attributable fractions (PAFs) of
prevalent tuberculosis to hyperglycaemia and HIV were
calculated separately for each country and for combined
estimates. These were calculated using the formula PAF
= ∑pk ' (θk − 1)/θk where p’ is the proportion of cases ex-
posed in the study population at exposure level k and θ
is the adjusted odds ratio. Given that θ and p’ were esti-
mated from the same data, the 95% confidence intervals
could be calculated using the following error factor for
(1-PAF):
Error factor ¼ exp 1:96
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
n1p
02V þ 2p0 θ−1ð Þ þ p0 1−p0ð Þ θ−1ð Þ2
n1 θ 1−p
0ð Þ þ p0½ 2
s
( )
where n1 is the total number of cases observed and V
the variance of the adjusted log odds ratio (the standard
error of the log odds ratio squared). Evidence for effect
modification by gender and HIV was explored. All data
analyses were performed using Stata 13.
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Results
The cross-sectional survey enrolled 57,809 (70 · 8% of
eligible) participants from 31,300 (88 · 6% of eligible)
households in Zambia and 32,792 (77 · 7% of eligible)
participants from 17,095 (85 · 3% of eligible) households
in Western Cape (Fig. 1). Evaluable sputum samples and
complete RBG results were obtained for 27,800 (48 · 1%
of enrolled) participants in Zambia and 11,367 (34 · 7%
of enrolled) participants in Western Cape. Data from
these participants were analysed. Comparison of individ-
uals with evaluable sputum samples with those with
non-evaluable samples in Zambia showed them to be
much the same (data presented as supplementary mater-
ial to the ZAMSTAR trial publication) [16].
Among Zambian and Western Cape participants,
15.9% and 16.1% respectively had a RBG concentration
≥7.0 mmol/L, and 1.5% and 2.8% respectively had a
RBG concentration ≥11.1 mmol/L. The prevalence of
tuberculosis was approximately 500 per 100,000 (0 · 5%)
among Zambian participants and approximately 2,500 per
100,000 (2 · 5%) among Western Cape participants.
Tuberculosis prevalence stratified by glycaemia and base-
line characteristics is shown in Tables 1 and 2.
Among individuals included in the analysis, HIV status
was determined by blood sampling for 23,067 (90 · 2%)
participants and by self-reported status for 2,501 (9 · 8%)
participants in Zambia. Corresponding values for
Western Cape participants are 10,106 (94 · 8%) and 551
(5 · 2%). Among participants with RBG results, 2,232
participants in Zambia and 710 in Western Cape had
missing data for both blood sampling and self-reported
HIV status.
Fig. 1 Number and flow of participants and cases in this cross sectional study in Zambia and the Western Cape of South Africa
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Among Zambian participants, as RBG concentration in-
creased, the unadjusted and adjusted odds of prevalent TB
initially increased compared to the baseline RBG concen-
tration <5.6 mmol/L, peaking at RBG concentration 9.0–
11.0 mmol/L (adjusted OR 4.31, 95% CI [2.07–8.97]).
Although the odds of prevalent TB did not continue to
increase with increasing RBG concentration beyond this,
the number of individuals with a RBG concentration
≥11.1 mmol/L was low and the confidence interval was
wide so there was still strong evidence of a linear associ-
ation between RBG concentration and TB prevalence
(p = 0.006) after adjusting for age, sex, household socio-
economic position, education, body mass index, HIV
status and geographical location (Table 1).
On multivariable analysis there was weak evidence of a
linear association between glucose concentration and TB
prevalence among Western Cape participants (p = 0.06).
In this location the adjusted odds of prevalent TB com-
pared to the baseline was greatest for individuals with a
RBG concentration ≥11.1 mmol/L (OR 2.49, 95% CI
[1.29–4.79], Table 2).
Unadjusted and adjusted odds ratios for prevalent TB
using sequential RBG cut-offs to give increasing levels of
hyperglycaemia are shown in Table 3. The findings from
Zambia and Western Cape, combined with fixed-effects
meta-analyses, showed increasing adjusted odds of preva-
lent tuberculosis for increasing cut-off levels of hypergly-
caemia, though the increase was small; and, across
successive cut-off levels, confidence intervals overlapped
(Table 4). There was no evidence that the adjusted odds
ratios differed between Zambia and Western Cape
(Table 4).
The evidence for association between hyperglycaemia
and prevalent tuberculosis strengthened from univariable
to multivariable analyses in both Zambia and the Western
Cape communities. In the Zambian communities the pre-
dominant negative confounding factors were body mass
index and HIV status. The Western Cape communities
had the same negative confounding factors, while the pre-
dominant positive confounding factor was age.
On combined analysis, there was evidence of a contri-
bution of hyperglycaemia to the population prevalence
of tuberculosis throughout the spectrum of hypergly-
caemia (Table 4). However, the PAFs of prevalent TB to
hyperglycaemia were small, particularly for the higher
RBG cut-offs. For RBG concentration ≥11.1 mmol/L the
PAF of prevalent TB was 0.99%, 95% CI [0.12–1.85].
When analysed as separate locations, the confidence in-
tervals for the PAFs were wide and showed less evidence
for a contribution of hyperglycaemia to the population
prevalence of tuberculosis in both Zambia and Western
Cape (Table 3).
When stratified by age, for the highest RBG cut-off, the
PAF of prevalent TB to hyperglycaemia increased with
increasing age in Western Cape, reflecting the higher
prevalence of hyperglycaemia in older age groups (Table 5).
In Zambia, for this highest RBG cut-off ≥11.1 mmol/L,
there remained little evidence for a contribution of hyper-
glycaemia to the population prevalence of tuberculosis des-
pite the rising prevalence of hyperglycaemia with increasing
age, though confidence intervals were wide (Table 5).
For purposes of comparison to HIV, the PAF of preva-
lent TB to HIV was 12.72%, 95% CI [7.70–17.47] in the
Zambian communities, and 11.72%, 95% CI [8.25–15.06]
in the Western Cape communities.
For purposes of comparison to self-reported known
diabetes, of individuals with a RBG <11.1 mmol/L, 1.7% in
Zambian and 6.8% in Western Cape communities re-
ported having a previous diagnosis of diabetes, and 0.3%
and 2.0% respectively reported being on treatment for dia-
betes. Of individuals with a RBG ≥11.1 mmol/L, 27.9% in
Zambian and 57.5% in Western Cape communities re-
ported having a previous diagnosis of diabetes, and 24.0%
and 49.1% respectively reported being on treatment for
diabetes. Incorporating participants with self-reported
previously diagnosed diabetes into the highest category of
hyperglycaemia made little difference to the odds ratio
point estimates in Zambia and reduced the association
seen with RBG concentration ≥11.1 mmol/L in Western
Cape towards the null. Defining diabetes by self-report,
the odds of prevalent TB for individuals with diabetes
compared to those without was 0.83, 95% CI [0.20–3.46]
in Zambia and 0.76, 95% CI [0.44–1.32] in Western Cape.
For individuals in Western Cape with self-reported dia-
betes and RBG ≥11.1 mmol/L the odds of prevalent TB
was 1.55, 95% CI [0.60–4.01] compared to individuals
who did not report diabetes. For those with self-reported
diabetes and RBG <11.1 mmol/L this odds ratio was 0.61,
95% CI [0.32–1.18].
Subgroup analyses were not possible for the Zambian
data using the highest RBG cut-off ≥11.1 mmol/L due to
limited data, and no difference was seen for gender and
HIV categories using the RBG cut-off ≥9.0 mmol/L. In the
Western Cape using the RBG cut-off ≥11.1 mmol/L, the
point estimate of the adjusted odds of hyperglycaemia on
prevalent tuberculosis was higher among women than
men (for men OR = 1 · 92, 95% CI [0 · 55–6 · 68]; for
women OR = 2 · 58, 95% CI [1 · 24–5 · 35]; but there was
no evidence the odds ratio differed for men and women,
test for interaction p = 0 · 68). It was higher among those
with HIV than those without HIV (among those with HIV
OR= 5 · 34, 95% CI [1 · 56–18 · 23]; among those without
HIV OR= 1 · 90, 95% CI [0 · 89–4 · 04]; but the evidence
for interaction was weak (p = 0 · 17)).
Discussion
This is the first ever population based study of prevalent
tuberculosis diagnosed microbiologically and glycaemia.
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We used participants who were randomly selected from
the community rather than exploring the association
among participants who had already been diagnosed with
tuberculosis or hyperglycaemia. Among the Zambian par-
ticipants of our study there was good evidence of a positive
linear association between hyperglycaemia and prevalent
tuberculosis, and weak evidence for the same association
in Western Cape. When data from the two locations were
combined, there was evidence of association between
hyperglycaemia and prevalent pulmonary tuberculosis
across the spectrum of hyperglycaemia. On combined ana-
lysis the odds of prevalent tuberculosis was greatest for
individuals with the highest level of glycaemia, though the
magnitude of association was small. Those with a RBG
concentration ≥11.1 mmol/L, had 2.15 times the odds of
prevalent tuberculosis than those with a RBG concentra-
tion <11.1 mmol/L.
This association seen in the study communities
between hyperglycaemia and prevalent tuberculosis is
consistent with the association seen elsewhere in the
world between diabetes and prevalent TB [17, 18] and
also between diabetes and active diagnosed TB [8–10].
Assuming causation, hyperglycaemia contributes little
to the prevalence of tuberculosis throughout the spectrum
of hyperglycaemia in the Zambian and Western Cape
populations. This suggests that hyperglycaemia has only a
small impact on the prevalence of TB in the study areas of
Zambia and Western Cape despite the positive association
seen between hyperglycaemia and prevalent TB in these
locations. When stratified by age, however, we can see that
the contribution of hyperglycaemia to the prevalence of
tuberculosis in Western Cape is greater for older age
groups, reflecting the higher prevalence of hyperglycaemia
among older individuals. The same trend is seen in the
Zambian study population, but the lower prevalence of
hyperglycaemia in this setting means that confidence in-
tervals are wide and point estimates remain low even for
the oldest age groups.
The combined odds ratios were weighted towards the
Western Cape estimates due to the larger number of in-
dividuals with hyperglycaemia and tuberculosis in this
setting, particularly for RBG concentration ≥11.1 mmol/
L. Given the uncertainty of the Zambian odds ratio for
this higher level of glycaemia the combined analyses
yield the more reliable conclusions. However, regardless
of which analysis is used, the conclusion remains the
same, that the contribution of hyperglycaemia to the
population prevalence of tuberculosis is low.
In this study we measured hyperglycaemia using a single
RBG test. To optimise the accuracy of the test research
Table 5 Population attributable fraction of prevalent tuberculosis to hyperglycaemia for Zambian and Western Cape communities,
stratified by age, using random blood glucose concentration cut-off 11.1 mmol/L
Age (years) Zambia Western Cape
Hyperglycaemia prevalence (%) PAF (95% CI) Hyperglycaemia prevalence (%) PAF (95% CI)
18–24 0.42 0.00 (0.00–0.96) 0.27 0.16 (0.00–0.52)
25–29 0.51 0.00 (0.00–1.16) 0.42 0.24 (0.00–0.70)
30–34 1.22 0.00 (0.00–2.72) 0.75 0.43 (0.00–1.05)
35–39 1.18 0.00 (0.00–2.63) 2.04 1.18 (0.07–2.28)
40–49 2.27 0.00 (0.00–4.95) 4.26 2.47 (0.67–4.24)
50–59 4.69 0.00 (0.00–9.88) 7.76 4.50 (1.70–7.22)
60+ 4.60 0.00 (0.00–9.70) 8.65 5.01 (1.97–7.97)
Total 1.45 0.00 (0.00–3.21) 2.83 1.64 (0.28–2.99)
PAF population attributable fraction, CI confidence interval; Hyperglycaemia defined as a random blood glucose concentration ≥11.1 mmol/L; Negative PAFs were
given a value of zero
Table 4 Combined adjusted odds ratios of prevalent tuberculosis for Zambia and Western Cape and associated population
attributable fractions of prevalent tuberculosis to hyperglycaemia for sequential random blood glucose concentration cut-offs
Random blood glucose
concentration cut-off (mmol/L)
Combined adjusted OR* P-value# I2p-value PAF (95% CI) of prevalent TB
to hyperglycaemia (%)
7.0 1.40 (1.07–1.84) 0.013 0.112 4.57 (1.27–7.77)
7.8 1.48 (1.06–2.07) 0.020 0.176 2.82 (0.64–4.95)
9.0 1.87 (1.21–2.90) 0.005 0.104 1.84 (0.56–3.11)
11.1 2.15 (1.17–3.94) 0.013 0.306 0.99 (0.12–1.85)
OR odds ratio, CI confidence interval, PAF population attributable fraction; ORs combined through fixed-effects meta-analysis; #Likelihood ratio tests; All analyses
accounted for the two-stage clustered sampling design through the use of a logistic regression model with random effects for enumeration area and inclusion of
region or community as a fixed effect; Negative PAFs were given a value of zero; *Adjusted for age, sex, HIV status, body mass index, household socioeconomic
position and education
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staff were carefully trained and tested, and the point-of-
care measure was carefully calibrated using standardised
control solution, although not validated against laboratory
glucose analyses. Use of this point-of-care test enabled
glucose measurement of many participants in a large-scale
field study located within the community. Use of a test
that is more complicated to administer, such as a fasting
blood glucose, oral glucose tolerance test or glycated
haemoglobin, would have been logistically challenging and
potentially less acceptable to participants, resulting in a
much lower uptake of eligible participants and possibly
introducing selection bias. Therefore, although not a test
to diagnose diabetes, it was felt that the use of a RBG test
was most likely to minimise overall bias and loss of study
power in this setting of a large-scale population survey,
spanning communities and countries. Therefore, rather
than diagnosing diabetes, we have measured glycaemia
and explored the effect of hyperglycaemia on tuberculosis
prevalence. RBG tests normally have good specificity but
sub-optimal sensitivity for diabetes [29, 30]. A study in
China found measurement of RBG concentration with a
cut off of 11 · 1 mmol/L to have a sensitivity for diabetes
of only 54 · 8% compared to an oral glucose tolerance test.
[31] This would suggest that association seen with hyper-
glycaemia based on RBG concentration would be an
under-estimate of any association with diabetes. However,
in the context of active TB disease the specificity of this
test for diabetes could also be reduced, as those with
stress-induced hyperglycaemia secondary to their TB dis-
ease could also have a high RBG concentration. This
would result in an over-estimate of the association with
TB based on RBG concentration, compared to association
with diabetes. A final consideration is a single RBG meas-
urement fails to give data on chronic hyperglycaemia, so
we are unable to explore the effect of chronic hypergly-
caemia on tuberculosis prevalence from these data. We
did explore the effect of participants having previously di-
agnosed diabetes who may be on treatment and therefore
may be normoglycaemic at the time of RBG testing but
have longer term hyperglycaemia. The number of these
participants were few in both Zambia and Western Cape
and when incorporated into the categories of hypergly-
caemia did not increase the odds ratio point estimates of
the association with prevalent TB in either study location.
Regardless of whether the hyperglycaemia measured was
due to diabetes, was a consequence of TB disease or was
transient from any other cause, the conclusion remains
that in our study communities hyperglycaemia contributes
little to the population prevalence of tuberculosis.
The substantial losses of evaluable respiratory samples
in this study resulted largely from a failure of the posi-
tive mycobacterial control to grow in two of the labora-
tories in Zambia, causing whole batches to be non-
evaluable. This has resulted in reduced study power, but
is unlikely to have introduced bias to the study results,
as the process could not have been associated with the
presence or absence of hyperglycaemia in the individuals
affected by these missing data. The missing glycaemic
data is similarly unlikely to produce bias and was prob-
ably the consequence of the lack of prioritisation during
data collection, a consequence of nesting this study
within a larger cluster-randomised trial. Therefore, this
too is unlikely to have been associated with the presence
or absence of disease and so is also unlikely to have in-
troduced substantial bias.
The participants in this study were randomly selected
from their communities and so are representative of the
general population within each community. The com-
munities included were from urban and peri-urban set-
tings and so rural populations are under-represented in
this study. The prevalence of both hyperglycaemia and
tuberculosis would therefore likely be lower in a general
population sample.
In subgroup analysis, the association between hyper-
glycaemia and prevalent TB among those with HIV was
stronger than among those without HIV, which could
suggest that hyperglycaemia and HIV work synergistic-
ally to increase one’s risk of TB, or could instead reflect
an increase in stress-induced hyperglycaemia among
those with HIV compared to those without HIV. These
findings should be seen as hypothesis generating as the
evidence for effect modification was weak and our data
are underpowered for formal assessment of effect
modification.
Conclusion
In our study communities in Zambia and Western Cape,
there is evidence for a positive linear association between
hyperglycaemia and prevalent pulmonary tuberculosis. On
combined analysis, individuals with RBG concentration
≥11.1 mmol/L had 2.15 times the odds of prevalent tu-
berculosis than individuals with a RBG concentration
<11.1 mmol/L. Despite this, assuming causation, hyper-
glycaemia contributes little to the tuberculosis prevalence
in our study communities. Investigation of the associations
between hyperglycaemia, diabetes and active diagnosed tu-
berculosis in these study communities would be a valuable
addition to the findings from this study, and would allow
for sub-group analysis of association with smear-negative,
smear-positive and drug-resistant tuberculosis.
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